MedTrace Logo

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

NCT00206219 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 477

Last updated 2011-01-27

No results posted yet for this study

Summary

This study is to compare ZD1839 (250mg and 500mg) versus methotrexate in head and neck cancer in terms of overall survival.

Conditions

  • Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

Gefitinib

DRUG

methotrexate

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Iressa Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2007-09-30
Completion
2007-09-30

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Brazil
  • Canada
  • Croatia
  • Czechia
  • Estonia
  • Greece
  • India
  • Israel
  • Italy
  • Latvia
  • Lithuania
  • Malaysia
  • Netherlands
  • Norway
  • Russia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206219 on ClinicalTrials.gov